
Pfizer and Valneva Report Promising Results as Lyme Disease Vaccine Candidate Shows High Efficacy in Phase 3 VALOR Trial
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer Inc. and Valneva SE announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its…












